PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition...


Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions. The company focuses on areas of high unmet medical need where neurobiological pathways provide a strong rationale for our pharmacological approach. Balance's experienced drug development team is committed to advancing products to deliver life-improving medicines that serve patients and their families. The company's principal areas of focus are sleep disorders and cognitive deficits.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.